Your browser doesn't support javascript.
loading
Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Aydilek, Enver; Wulf, Gerald; Schwarz, Friedrich; Bacher, Ulrike; Rummel, Mathias; Stiefel, Olga; Kerkhoff, Andrea; Maulhardt, Markus; Melchardt, Thomas; Pabst, Thomas; Lenz, Georg; Shumilov, Evgenii.
Afiliação
  • Aydilek E; Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Wulf G; Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Schwarz F; Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Bacher U; Campus Institute for Dynamics of Biological Networks, Georg August University, Göttingen, Germany.
  • Rummel M; Department of Hematology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Stiefel O; Department of Hematology, Clinic for Haematology and Medical Oncology, Justus Liebig University Hospital, Gießen, Germany.
  • Kerkhoff A; Division of Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Linz, Austria.
  • Maulhardt M; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
  • Melchardt T; Department for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
  • Pabst T; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, Salzburg, Austria.
  • Lenz G; Department of Medical Oncology, Inselspital Bern University Hospital, Bern, Switzerland.
  • Shumilov E; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
Cancer Med ; 13(10): e7289, 2024 May.
Article em En | MEDLINE | ID: mdl-38770551
ABSTRACT

BACKGROUND:

Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.

METHODS:

In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).

RESULTS:

On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.

CONCLUSIONS:

In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Célula do Manto / Ensaios de Uso Compassivo Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Célula do Manto / Ensaios de Uso Compassivo Idioma: En Ano de publicação: 2024 Tipo de documento: Article